Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Caine, S. Perlberg, R. Gordon (1975)
The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study.The Journal of urology, 114 4
M. Nadji, S. Tabei, A. Castro, T. Chu, G. Murphy, Ming Wang, A. Morales (1981)
Prostatic‐specific antigen: An immunohistologic marker for prostatic neoplasmsCancer, 48
H. Mori, M. Maki, K. Oishi, M. Jaye, K. Igarashi, O. Yoshida, Masakazu Hatanaka (1990)
Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasiaThe Prostate, 16
R. Bosch, D. Griffiths, J. Blom, F. Schroeder (1989)
Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters.The Journal of urology, 141 1
N. Roos, J. Wennberg, D. Malenka, E. Fisher, Klim McPherson, T. Andersen, Marsha Cohen, E. Ramsey (1989)
Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia.The New England journal of medicine, 320 17
P. Walsh, J. Madden, M. Harrod, J. Goldstein, P. Macdonald, Jean Wilson (1974)
Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.The New England journal of medicine, 291 18
Liang Liang, Heiss Heiss, Cheung Cheung, Reynolds Reynolds, Rasmusson Rasmusson (1984)
4‐Aza steroidal 5α‐reductase inhibitors without affinity for the androgen receptorJ Biol Chem, 259
J. Geller (1990)
Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.The Journal of clinical endocrinology and metabolism, 71 6
G. Drach, T. Layton, W. Binard (1979)
Male peak urinary flow rate: relationships to volume voided and age.The Journal of urology, 122 2
C. Peters, P. Walsh (1987)
The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.The New England journal of medicine, 317 10
(1968)
The conversion of testosterone to 5a-androstan-l7P-ol-3-one by rat prostate
J. Imperato-McGinley, L. Guerrero, T. Gautier, R. Peterson (1974)
Steroid 5α-Reductase Deficiency in Man: An Inherited Form of Male PseudohermaphroditismScience, 186
S. Berry, D. Coffey, P. Walsh, L. Ewing (1984)
The development of human benign prostatic hyperplasia with age.The Journal of urology, 132 3
S. Boyarsky, G. Jones, D. Paulson, Prout Gr (1976)
A new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophy.Transactions of the American Association of Genito-Urinary Surgeons, 68
(1984)
Rasmusson GH: 4-Aza steroidal 5a-reductase inhibitors without affinity for the androgen receptor
(1979)
Effect of megestrol acetate on uroflow rates in patients with benign prostate hypertrophy
(1991)
Outcome analysis after treatment for benign prostatic hyperplasia (BPH) by various modalities. A confidence profile analysis
The effects of finasteride, a potent 5α‐reductase inhibitor, were assessed in 750 patients with benign prostatic hyperplasia (BPH) in a multicenter, double‐blind, placebo‐controlled study. Patients were randomized to finasteride, 1 or 5 mg, or placebo, daily for 12 months. The following changes were seen with finasteride 5 mg after 12 months: (1) Serum dihydrotestosterone decreased by 62% compared to no change with placebo (P < 0.001); (2) serum prostate‐specific antigen (PSA) decreased by 46% compared to no change with placebo (P < 0.001); (3) prostate volume was reduced by 22% compared to a 5% decrease with placebo (P < 0.001); (4) maximum urinary flow rate increased by 1.7 ml/sec compared to a 0.4 ml/sec increase with placebo (P < 0.025); (5) total urinary symptom scores decreased by 3.3 points compared to a 2.0 point decrease with placebo (P = 0.005), and (6) obstructive symptom scores decreased by 2.1 points compared to a 1.4 point decrease with placebo (P = 0.017). The effects of finasteride 1 mg were similar to 5 mg, except in urinary symptoms, where no significant differences between 1 mg and placebo were seen. Patients treated with 5 mg finasteride demonstrated significantly greater improvements in urological status (assessed by the investigator) and the troublesome symptom score, compared to placebo. Treatment with finasteride was well tolerated. We conclude that finasteride is an effective medical therapy for a significant proportion of patients with BPH. © 1993 Wiley‐Liss, Inc.
The Prostate – Wiley
Published: Jan 1, 1993
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.